Maravai LifeSciences Holdings (Maravai LifeSciences Holdings) Total Inventories : $49.8 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Maravai LifeSciences Holdings Total Inventories?

Maravai LifeSciences Holdings's total inventories for the quarter that ended in Mar. 2024 was $49.8 Mil. Maravai LifeSciences Holdings's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $50.6 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Maravai LifeSciences Holdings's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-3.17.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Maravai LifeSciences Holdings's Days Inventory for the three months ended in Mar. 2024 was 120.50.

Inventory Turnover measures how fast the company turns over its inventory within a year. Maravai LifeSciences Holdings's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.76.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Maravai LifeSciences Holdings's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.79.

Maravai LifeSciences Holdings Total Inventories Historical Data

The historical data trend for Maravai LifeSciences Holdings's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maravai LifeSciences Holdings Total Inventories Chart

Maravai LifeSciences Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

14.20

33.30

51.56

43.15

51.40

Maravai LifeSciences Holdings Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Inventories	Get a 7-Day Free Trial															54.82	47.40	49.14	51.40	49.85

Maravai LifeSciences Holdings Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Maravai LifeSciences Holdings (NAS:MRVI) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Maravai LifeSciences Holdings's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

	Net-Net Working Capital Per Share (Q: Mar. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(561.691	+	0.75 * 36.685	+	0.5 * 49.846	-	667.252
-	0	-	366.73)	/	132.655
=	-3.17

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Maravai LifeSciences Holdings's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	50.6215	/	38.335	*	365 / 4
	=	120.50

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Maravai LifeSciences Holdings's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	38.335	/	50.6215
	=	0.76

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Maravai LifeSciences Holdings's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	50.6215	/	64.179
	=	0.79

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Maravai LifeSciences Holdings Total Inventories Related Terms

Thank you for viewing the detailed overview of Maravai LifeSciences Holdings's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Maravai LifeSciences Holdings (Maravai LifeSciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maravai LifeSciences Holdings Inc (NAS:MRVI) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

MRVI:Mexico MAR:Germany

Address

10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121

Website

https://www.maravai.com

Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Executives

John A Deford	director	C R BARD INC, 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Rebecca Buzzeo	officer: See Remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Andrew Burch	officer: See Remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Martin William E. Iii	officer: See remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Peter Michael Leddy	officer: See Remarks	1620 FARADAY AVE, CARLSBAD CA 92008
Carl Hull	director, officer: Chief Executive Officer	300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Gregory T Lucier	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kurt Oreshack	officer: General Counsel	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Murali Prahalad	director	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Lisa Sellers	officer: See Remarks	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Susannah Gray	director	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Robert B Hance	director	300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Jessica Hopfield	director	C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Brian Neel	officer: See Remarks	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Christine Dolan	officer: See Remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121